Efficacy and safety analysis of anlotinib combined with immunotherapy as second-line therapy for advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Shi, Q. [1 ]
Xie, Q. [1 ]
Lin, H. [1 ]
He, Y. [2 ]
Zheng, X. [1 ]
Zhou, Z. [1 ]
机构：
[1] Fuzhou Pulm Hosp Fujian, Oncol, Fuzhou, Peoples R China
[2] Quanzhou First Hosp, Oncol, Quanzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.363
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
324P
引用
收藏
页码：S1568 / S1568
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of second-line immunotherapy in patients with advanced non-small cell lung cancer
    Sanchez Escudero, Laura
    Cobelas Cartagena, Stephanie S.
    Sanchez Esperilla, Maria
    Bayo, Juan L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Zhong, R.
    Zhong, H.
    Zhang, B.
    Zhang, W.
    Shi, C.
    Qian, J.
    Han, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S129 - S129
  • [3] Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
    Hirata, Tsuyoshi
    Hakozaki, Taiki
    [J]. JOURNAL OF THORACIC DISEASE, 2023, 15 (07) : 3554 - 3556
  • [4] The efficacy and safety profile of anlotinib plus docetaxel as second-line treatment in advanced non-small cell lung cancer.
    Xu, Zhiqiao
    Zhang, Yan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Efficacy and safety of anlotinib monotherapy or combination therapy as second-line therapy in EGFR-wild-type non-small cell lung cancer (NSCLC) patients
    Guo, J.
    Wang, X.
    Zheng, F.
    Zhao, G.
    Wang, Y.
    Hu, Y.
    Liu, P.
    Ma, C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1012 - S1012
  • [6] SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Cullen, M.
    [J]. LUNG CANCER, 2009, 64 : S13 - S13
  • [7] Immunotherapy as a second-line or later treatment modality for advanced non-small cell lung cancer: A review of safety and efficacy
    Geraci, Emily
    Chablani, Lipika
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 152
  • [8] Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Han, B.
    Chu, T.
    Zhang, X.
    Zhong, H.
    Zhang, B.
    Wang, H.
    Gu, A.
    Zhang, W.
    Shi, C.
    Zhong, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S398 - S398
  • [9] Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Shi, C.
    Zhong, H.
    Zhang, W.
    Zhang, B.
    Zhong, R.
    Zhang, X.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S646 - S647
  • [10] Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Ardizzoni, A
    Tiseo, M
    [J]. JOURNAL OF CHEMOTHERAPY, 2004, 16 : 104 - 107
12345